Physician profile
David Killion
NPI 1619979952
$4,511.70
in general payments reported to CMS, 2019-2025
38 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $526 · 2021: $536 · 2022: $689 · 2023: $876 · 2024: $851 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $726.57 | 2023-2025 | Orgovyx, Gemtesa |
| Coloplast Corp | $428.40 | 2019-2024 | Speedicath, Saffron |
| Myovant Sciences INC. | $380.98 | 2021-2022 | |
| 180 Medical, INC. | $374.69 | 2019-2024 | Gentlecath |
| Astellas Pharma US INC | $346.05 | 2019-2024 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $321.70 | 2019-2025 | |
| Amgen INC. | $258.14 | 2019-2020 | |
| Janssen Biotech, INC. | $206.16 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $192.71 | 2019-2024 | Provenge |
| Pfizer INC. | $186.36 | 2019-2024 | |
| Tolmar Pharmaceuticals, INC. | $104.87 | 2022 | |
| Boston Scientific Corporation | $100.22 | 2019-2024 | Advantage System, Ams 800 Artificial Urinary Sphincter |
| Abbvie INC. | $92.15 | 2021-2025 | |
| Urogen Pharma, INC. | $84.56 | 2023-2024 | Jelmyto |
| Teleflex LLC | $80.97 | 2022-2024 | Solesta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Killion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.